Intra-Cellular Therapies announced that it has commenced an underwritten public offering of $500M of shares of its common stock. J.P. Morgan, Leerink Partners, BofA Securities, Morgan Stanley and RBC Capital Markets are acting as joint book-running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Intra-Cellular Advances Depression Treatment with Lumateperone
- Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
- Needham remains positive on Intra-Cellular ahead of Caplyta readouts
- Intra-Cellular Therapies Announces Executive Leadership Changes
- Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes